ICON PLC
ICLR
查看详细走势图
150.590USD
+5.200+3.58%
收盘 02/06, 16:00（美东）报价延迟15分钟
11.50B总市值
20.17市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.58%
5天
-16.45%
1月
-25.26%
6月
-3.11%
今年开始到现在
-17.36%
1年
-23.14%
查看详细走势图
TradingKey ICON PLC股票评分
单位: USD 更新时间: 2026-02-06操作建议
ICON PLC当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名37/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价205.56。中期看，股价处于平稳状态。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
ICON PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
极度看空
ICON PLC亮点
亮点风险
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
行业龙头
公司营业收入处于行业前列，最新年度总收入8.28B美元
利润高增长
公司净利润处于行业前列，最新年度总收入8.28B美元
估值低估
公司最新PE估值20.17，处于3年历史低位
机构减仓
最新机构持股81.22M股，环比减少16.62%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值643.00
活跃度降低
近期活跃度降低，过去20天平均换手率0.06
分析师目标
根据
18
位分析师
买入
评级
205.563
目标均价
+41.39%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
ICON PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
ICON PLC简介
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
公司代码ICLR
公司ICON PLC
CEOBalfe (Barry Edward)
网址https://www.iconplc.com/
相关品种
